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stimulationAbstract Purpose: To develop rotigotine-loaded implants (RI) to achieve continuous release of
rotigotine for long duration for the treatment of Parkinson’s disease (PD).
Methods: RI was prepared by hot-melt extrusion method using poly (lactide-co-glycolide)
(PLGA) as the matrix. In vitro drug release was optimized by drug loading, melting temperature
during preparing process and additives. The surface and internal morphology of RI was imaged
by SEM. The in vivo release profile of RI was investigated on rat.
Results: RI prepared with PLGA 7525 5A showed sustained release of 40 days while suffering a
lag phase, which was significantly shortened by blending 5050 2A and mannitol in the matrix. RI
prepared by 7525 5A/5050 2A/mannitol = 55:10:5 (rotigotine 30%) showed a 40-day sustained
release in vivo with no lag phase. The drug release from RI was also affected by drug loading
and melting temperature probably due to the drug state existed in the implant. The evolution of
implants during release process was correlated well with the drug release kinetics.
Conclusion: RI could achieve sustained drug release for 40 days which could supply an alterna-
tive of continuous dopaminergic stimulation (CDS) for the treatment of PD.
 2016 Production and Hosting by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Parkinson’s disease (PD) is the second most common neurode-
generative disorder worldwide which results primarily from the
death of dopaminergic neurons in the substantia nigra
(William and Przedborski, 2003) and it affects about 1–1.5%
of the population over 60 years of age (De Lau and Breteler,
364 A. Wang et al.2006). Levodopa continues to be gold standard for the symp-
tomatic treatment of PD (Olanow et al., 2006a–c). However,
after a few years of treatment with levodopa most parkinso-
nian patients develop motor complications, notably
levodopa-induced dyskinesias (LID), which are difficult to
control and significantly impair the quality of life. The appear-
ance of LID may be related with the discontinuous stimulation
toward dopamine receptor (Olanow et al., 2006a–c; Nyholm,
2007). Thus a new therapeutic concept of continuous
dopaminergic stimulation (CDS) was proposed for the treat-
ment of PD (Olanow et al., 2006a–c). Theoretically, CDS
can continuously provide dopamine or a dopamine agonist
to striatal dopamine receptors which should mimic the contin-
uous stimulation of dopaminergic receptors in the normal
manner to benefit the PD patients (Olanow et al., 2000,
2006a–c; Nutt, 2007). L-DOPA and dopamine agonists have
inspired the therapeutic concept of CDS, which has been devel-
oped and received considerable attention for treatment of PD
(Olanow et al., 2000, 2006a–c; Nutt, 2007; Nutt et al., 2000).
Rotigotine is a non-ergoline agonist of dopamine D3/D2/
D1 receptor indicated for the treatment of PD. It was devel-
oped as transdermal patch, Neupro, to provide 24-h contin-
uous drug levels which could improve efficacy and reduce
motor complications. However, there is many side effects with
skin patches, eg the different absorption rate of drug through
the different part of skin and the skin of different person and
the skin irritation after long-term application (Sujith and Lane,
2009). Therefore, we have developed rotigotine-loaded micro-
spheres in our previous study which could supply a 14-day sus-
tained drug release (Wang et al., 2012). As PD patients require
long-term treatment, it is necessary to develop a much longer
sustained release preparation of rotigotine to achieve CDS
for the treatment of PD and to improve the compliance of
the PD patients significantly.
Polymeric implantable drug delivery systems have shown
significant potential for systemic delivery of various therapeu-
tic drugs (Jain et al., 2005) and proteins (Hafeman et al., 2008)
at a controlled rate over the past few decades. Several poly-
meric implants, such as goserelin (Zoladex), leuprolide (Via-
dur) etc. (Furr and Hutchinson, 1991), are approved by the
FDA. Due to their slow-release kinetics, implants can provide
continuous drug release ranging from months to >1 year,
which improves the patient compliance significantly
(Dashand and Cudworth, 1998). Hot-melt extrusion has been
developed as a new preparation technique for the implant in
the present time, which has some advantages, including ease
of use and lack of residual solvents, decreased costs and envi-
ronmental hazards (Forster et al., 2001; Crowley et al., 2004).
Thus, the present study was designed to develop rotigotine-
loaded implant to achieve much longer sustained release of
rotigotine for the treatment of PD. The factors affecting drug
release from the implant were investigated to obtain longer
sustained release period. In vivo release behavior was also stud-
ied on rats.
2. Materials and methods
2.1. Materials and animals
PLGA 7525 5A (lactide/glycolide ratio, 75/25; Mw, 72,000),
and PLGA 5050 2A (lactide/glycolide ratio, 50/50; Mw,18,000) were purchased from Lakeshore Biomaterials, USA.
Rotigotine was obtained from Shandong Luye Pharmaceuti-
cals (Yantai, China). HPLC grade acetonitrile and methanol
were supplied by Merck Specialities Private Ltd. (USA). All
other reagents used in this study were analytical grade.
Male Sprague–Dawley rats (200–250 g) used in the pharma-
cokinetics study were obtained from the Experimental Animal
Center of Shandong Luye Pharmaceutical Co., Ltd. (Yantai,
China). All of the experiments were carried out in accordance
with the ‘Principles of Laboratory Animal Care’ (NIH publica-
tion No. 85-23, revised 1985) and the Experimental Animal
Research Committee at Yantai University.
2.2. Preparation of rotigotine-loaded implants (RI)
Rotigotine-loaded implants were prepared by hot-melt extru-
sion method. The drug and PLGA were weighed at the selected
proportions as listed in Table 1 and gently ground in a oscillat-
ing miller (MM400 Retsch GmbH, Germany) for 3 min
(25 Hz s1) to achieve uniformity of powder. The extrusion
process was performed using a twin screw extruder (HAAKE
MiniCTW, Thermo Fisher Scientific, Germany) and the down-
stream processing equipment. The blended powders were man-
ually transferred to the preheated barrel and kept for 10 min
before extruded from the extruder. The operating temperature
changed with formulation as listed in Table 1. The extrudate
produced was rod-shaped and about 1 mm in diameter. The
rods were cut into implants of 3 mm in length.
2.3. In vitro characterization and evaluation
2.3.1. Differential scanning calorimetry (DSC) analysis
DSC study was carried out to investigate the thermal charac-
teristics of RI. A DSC 822e instrument (Mettler Toledo,
Switzerland) was used for the study. Approximately 5 mg of
the sample was heated in an open Al-crucible pan at a rate
of 10 C/min within a temperature range of 0 –170 C under
a 20 mL/min nitrogen flow.
2.3.2. Scanning electron microscopy (SEM) imaging
The morphologies (surface and cross-section) of the implants
retrieved from release medium during release process were
imaged by scanning electron microscope (SEM) (JSM-840,
JEOL, Japan). The retrieved implants were taken out at preset
time. Before visualization, the implants were gently washed
with distilled water, blotted with wipes to dry off excess water,
and then lyophilized for 48 h. The cross-section of the implants
was obtained by first freezing the implants in liquid nitrogen
and then breaking off by tweezers. Samples were fixed on
metal sample holders and sputter coated with gold using a
sputter coater.
2.3.3. Drug loading
RI of each formulation were accurately weighed and dissolved
in acetonitrile, and subsequently 0.01 M hydrochloric acid
solution was added up to 100 mL. The obtained solution was
filtered by a 0.45 lm microporous membrane and then ana-
lyzed by HPLC. The mobile phase consisted of acetonitrile
and 0.2% H3PO4 (40:60, v/v). The flow rate was maintained
at 1 mL/min and UV-detection was performed at 230 nm.
Table 1 Characteristics of the rotigotine-loaded implants formulations.
Formulation Feed ratios of implant Melting
temperature (C)
Drug loading
(Mean ± SD, n= 10, %)
Rotigotine (%) PLGA 7525 5A (%) PLGA 5050 2A (%) Additive (%)
1 20 80 – – 80 19.1 ± 0.3
2 25 75 – – 80 24.3 ± 0.5
3 30 70 – – 80 29.3 ± 0.3
4 35 65 – – 80 34.1 ± 0.4
5 30 70 – – 85 28.7 ± 0.6
6 30 70 – – 90 29.4 ± 0.3
7 30 60 10 – 80 28.4 ± 0.7
8 30 50 20 – 80 29.2 ± 0.4
9 30 40 30 – 80 30.6 ± 0.2
10 30 60 – Mannitol (10) 85 29.8 ± 0.8
11 30 60 – Cyclodextrin (10) 85 30.1 ± 0.4
12 30 55 10 Mannitol (5) 85 29.6 ± 0.7
13 30 55 10 Cyclodextrin (5) 85 31.1 ± 0.9
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Figure 1 Effect of drug loading (20%, 25%, 30% and 35%) on
drug release from RI.
Preparation and evaluation of rotigotine-loaded implant 365The actual drug loading of implant was then calculated. To
evaluate the homogeneity of drug distribution each experimen-
tal datum was generated from 10 implants randomly chosen
from each batch and expressed as mean value with standard
deviation (SD).
2.3.4. In vitro drug release studies
The in vitro release study was carried out in triplicate in a shak-
ing water bath. Each implant sample (10–11 mg) was accu-
rately weighed and placed in 25 mL vial containing 10 mL
acetate buffer solution (pH = 4.5) with 0.2% SDS and
0.01% Tween-80 under constant oscillation at 50 rpm. At pre-
determined time points, samples of 8 mL were removed from
the vial, and replaced by fresh medium. Samples were analyzed
by HPLC method as described above.
2.4. Pharmacokinetics study
Rat (n= 6 per formulation) was injected subcutaneously at
the dorsal area with RI at the drug dose of 30 mg/kg/40 d by
a special syringe (a syringe for the implant with a needle diam-
eter of 1.1 mm). Blood samples were collected at pre-setintervals before and after drug administration (30 min, 1 h,
3 h, 1 d, 3 d, 5–50 d). The samples obtained were immediately
centrifuged at 10,000 rpm and the plasmas were stored at
35 C before analysis. Rotigotine was analyzed by LC-MS/
MS as described previously (Ma et al., 2006). The HPLC sys-
tem (Agilent 1100 series) consisted of a binary pump and a
Zorbax C18 column. The mobile phase was acetonitrile-
1 mM ammonium acetate (75:25, v/v) and the flow-rate is
0.30 mL/min. The detection was performed with a TSQ Quan-
tum Access mass spectrometer (Thermo Fisher Scientific Inc.,
USA) operating in the positive ion mode. Multiple reaction
monitoring at unit resolution involved transitions of the proto-
nated forms of rotigotine at m/z 316.2? 147.1 and diazepam
at m/z 285.4? 193.1. The optimized MS conditions were as
follows: curtain gas, gas 1 and gas 2 (all nitrogen) at 15, 50
and 50 psi, respectively; ion spray voltage, 5500 V; source tem-
perature, 500 C; declustering potentials, 50 V for rotigotine
and 160 V for diazepam; the collision gas was set at 3 psi.
3. Results and discussion
3.1. In vitro characterization of RI
All implants prepared in this study were smooth and similar in
appearance, presenting somewhat tough characteristics. The
length of implant was cut into about 3 mm.
Drug contents of RI were analyzed to determine the unifor-
mity of drug distribution and the amount of drug incorporated
in each implant. The drug loading of all implants is shown in
Table 1. The drug content for all implants was consistent with
the theoretical drug-loading, indicating that the implants were
uniform with homogenous dispersion and the fabrication pro-
cess was suitable.
3.2. Effects of drug loading on drug release
The effect of drug loading on drug release from RI was evalu-
ated in this study. Fig. 1 shows the release profiles of RI with
different drug loading of 20%, 25%, 30% and 35% (w/w). It
was found that drug release from RI with 20% drug loading
was faster than the others and there was no significant differ-
ence in the release profile among implants with 25%, 30% and
35% drug loading. The drug state existed in the implant was
Figure 2 DSC thermograms of rotigotine (A), PLGA 7525 5A (B), the physical mixture of them (C) and RI with 20% (D), 25% (E),
30% (F) and 35% (G) drug loading.
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Figure 3 Effect of melting temperature (80 C, 85 C and 90 C)
on drug release from RI.
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Preparation and evaluation of rotigotine-loaded implant 367investigated by DSC analysis to explore the reason. Fig. 2 dis-
plays the DSC thermograms of rotigotine, PLGA, physical
mixture of the drug and PLGA and RI with different drug
loading. In the DSC thermograms, an endothermic peak of
rotigotine was found for RI with 25%, 30% and 35% drug
loading, demonstrating that rotigotine existed as a micro-
crystal state in implants. Furthermore, the peak intensity was
proportional to drug loading which indicated that the degree
of drug crystallization increased as drug content increased.
In contrast, no rotigotine peak was found in DSC thermogram
of RI with 20% drug loading, indicating that the amorphous
or molecular state of rotigotine dispersed in implants. The dif-
ference of drug state in RI with different drug loading may be
attributed to the saturated solubility of rotigotine in the PLGA
matrix. The results suggested that the drug state existed in the
implant is closely related with the drug release.
3.3. Effects of melting temperature on drug release
The influence of melting temperature (80 C, 85 C and 90 C)
during preparing process on drug release from RI was also
investigated with the same drug loading. As shown in Fig. 3,0 10 20 30 40 50
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Figure 4 Effect of polymer on drug release from RI.F
inthe drug release from RI prepared by 80 C melting tempera-
ture implants was far slower than 85 C and 90 C and there
is almost no difference of the release profile between RI pre-
pared by 85 C and 90 C melting temperature. DSC analysis
(figure not shown) of these implants showed that an endother-
mic peak of rotigotine was appeared in RI prepared by 80 C
melting temperature which was not observed for RI prepared
by 85 C and 90 C melting temperature. It was proved that
the melting temperature prepared for the implant can affect
the drug release by altering the drug physical state existed in
the implant. In this study, to achieve slow drug release kinetics,
low temperature was used beyond the melting temperature of
the materials.
3.4. Effects of polymer on drug release
The polymer is one of the determined factors to control the
rate of drug release from the polymeric matrix. Thus, different
implants were prepared by single or blending polymers to opti-
mize the drug release. Fig. 4 shows the in vitro drug release
profiles of RI prepared by single polymer PLGA 7525 5A
and blending polymers of 7525 5A and 5050 2A in different
proportions. RI prepared from single polymer of PLGA
7525 5A displayed a 40-day sustained release while with a
10-day lag phase. It was observed that the lag phase was signif-
icantly shortened as blending PLGA 5050 2A in the matrix. As
the content of 5050 2A increased, the drug release rate
increased and the lag phase shortened. This can be attributed
to the fast degradation of 5050 2A, which will cause the chan-
nels in the matrix. As the content of 5050 2A increased to 30%,
the release period was shortened to 30 days.
3.5. Effects of hydrophilic additives on drug release
Addition of certain excipients in the polymeric matrix could
influence the drug release significantly by changing the matrix
lipophilicity, matrix porosity, microclimate pH and/or poly-
mer drug interactions (Desai et al., 2008; Shyam et al.,
2011). Therefore, further investigation was conducted to mod-
ify the lag phase by adding hydrophilic substance. The aque-
ous channels formed by the hydrophilic substance in the
Figure 6 SEM photographs showing surface morphologies of RI. (A) Before drug release; (B) after 3-day drug release; (C) after 12-day
drug release. All photographs were obtained at 1000 magnification.
Figure 7 Photographs showing cross-section morphologies of RI of formulation: (A) the whole cross-section (50), (A1) the interior and
(A2) the exterior of the implant before drug release; (B) the whole cross-section (50), (B1) the interior and (B2) the exterior of the implant
after 3-day drug release; (C) the whole cross-section (50), (C1) the interior and (C2) the exterior of the implant after 9-day drug release;
(C) the whole cross-section (50), (D1) the interior and (D2) the exterior (500) of the implant after 12-day drug release; All other
photographs were obtained at 1000 magnification.
368 A. Wang et al.matrix were expected to facilitate the drug diffusion in the ini-
tial release to shorten the lag phase (Ma et al., 2006).
Fig. 5 displays the in vitro release profiles of RI containing
different water-soluble additives (mannitol, cyclodextrin). It
can be seen that the drug release from these implants with
addition hydrophilic substance follows three-phase release
kinetics, initially rapid release, subsequently slow release andthen rapid release again. However the lag phase was still
existed after initial burst release with the implant prepared
with single polymer of 7525 5A. While the implant was pre-
pared with blending polymers of 7525 5A and 5050 2A, the
lag phase was significantly shortened in which both the
water-soluble additives and 5050 2A played important roles
in eliminating the lag phase.
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after administration of RI. Each point represents mean ± SD
(n= 6).
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Structural evolution of RI prepared by PLGA 7525 5A during
release period was imaged by SEM. The samples before in vitro
release, after 3, 9 and 12-day release were taken out for SEM
study. Samples with longer release period were too vulnerable
to remove. Both the surface and the cross-section were dense
and devoid of pores before release (Figs. 6A and 7A). After
3-day drug release, a few pores could be observed on the sur-
face of the implant (Fig. 6B). Moreover, it could be seen that a
thin layer with osteoporosis structures existed in the surface of
the implant, and the internal structure of the implant was
almost the same as that before release (Fig. 7B, B1 and B2).
After 9-day drug release, it was noteworthy that there existed
many pores in the surface of the implants (figure not shown),
which was consistent with the exterior of the cross-section
morphologies (Fig. 7C2). There were two layers with different
structure in the cross-section of the implant and the exterior
layer of osteoporosis structure was thicker than before
(Fig. 7C). After 12-day drug release, more pores could be seen
in the exterior layer of the implant, and the size was larger than
before (Fig. 6C). It was obviously that many pores also gener-
ated in the interior structure of the implant (Fig. 7D2). These
structures were exactly associated with the release profile as
shown in Fig. 1 suggesting that the drug release from the
implant was controlled by erosion of the matrix and the diffu-
sion of the drug through the layer.
3.7. In vivo drug release
According to the in vitro release profiles, five formulations of
RI were selected to investigate the in vivo release behaviors
on rat (Fig. 8). It was observed that RI prepared with single
polymer of 7525 5A displayed a 40-day sustained release while
with a lag phase of about 10 days. The addition of PLGA 5050
2A can significantly shorten the lag phase. With the content of
5050 2A increased from 20% to 30%, the lag phase disap-
peared accompanied by the release period was shortened to30 days with high initial release. This can be attributed to
the fast degradation of PLGA 5050 2A. As the content of
5050 2A increased, the channels formed by the degradation
of 5050 2A increased which facilitate the drug diffusion from
the internal of the implant and the water molecular penetrates
into the PLGA chains promoting the polymer degradation.
Formulation 7, which was prepared with 7525 5A/5050 2A/
rotigotine = 60:10:30, showed a sustained release period about
40 days. Further, with the addition of mannitol of 5% (For-
mulation 12), the drug release was more steady which was sup-
posed to achieve continuous dopaminergic stimulation for the
treatment of PD with Cmax of 3.39 ± 0.31 ng/mL on 15th day
and the average concentration of 1.94 ± 0.39 ng/mL.
4. Conclusion
In this study, a sustaineddrug delivery system, rotigotine-loaded
implant was successfully developed by hot-melt extrusion
method. The optimized formulation of RI can achieve sustained
drug release for about 40 days with no lag phase, indicating a
good potential CDS treatment of PD. The release of drug from
implant was affected by the polymer, drug loading and melting
temperature. The structural evolution of implants during release
periodplayedanimportantrole inunderstandingthedrugrelease
mechanism. The RI could supply a convenient and practical
alternative of CDS treatment for PD.
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